| 摘要 |
<p>Compounds of the formula (I); wherein R1 is a member selected from the group consisting of C1-C8alkyl, arylC0-C8alkyl, C3-C12cycloalkyl and heterocyclyl, Y1 is selected from the group consisting of a bond, C(R5)2, NR5 and O; Y2 is selected from the group consisting of a bond, NR5 and O; each R2, R3 and R5 is independently selected from the group consisting of H, alkyl and COR6; A is heterocyclyl, optionally substituted with from 1 to 2 R7 substituents; L is selected from the group consisting of a direct bond, C1-C12alkylene, C1-C12heteroalkylene, C3-C6cycloalkylene, arylene, heteroarylene,-CO-,-SOin-and-Se-; R4 is selected from the group consisting of H, C1C8alkyl, C2-C6alkenyl, C2-C6alkynyl, C1,-C8heteroalkyl, arylC0-C8alkyl, C3C,12cycloalkyl and heterocyclyl, are claimed. The compounds are inhibitors of the soluble epoxide hydrolase (sEH) and useful for the treatment of hypertension, inflammation, adult respiratory distress syndrome; diabetic complications; end stage renal disease; Raynaud syndrome and arthritis. ® KIPO & WIPO 2009</p> |
